SGS Life Science Services (LSS) announced today that it is expanding its R&D/QC operations in North America. SGS Life Science Services R&D/QC division performs method development and quality control testing for the pharmaceutical, biopharmaceutical, medical device, chemicals and cosmetics markets. These cGMP services are currently performed out of three US-FDA registered sites in North America. The market for pharmaceutical contract testing is growing at 10–15% per annum. To meet this demand, SGS LSS will be doubling and tripling their facilities in Chicago and Toronto.

SGS has been operating its Life Science Services division in Canada since 1984, offering analytical chemistry, microbiology, and method development and validation. The existing SGS LSS facility located in the Toronto suburbs of Mississauga has been around since 1987. The new facility, also located in Mississauga, will triple the space from 15,000 square feet to 46,000 square feet. SGS LSS anticipates doubling its technical resources to handle new business opportunities. Concurrent with the move to the new facility, SGS Life Science Services R&D/QC will expand its capabilities in Canada by offering testing services for the analysis and characterization of biopharmaceuticals. The move is currently underway in phases and is expected to be complete by September.

In the US, SGS Life Science Services’ sites include a 35,000 square feet facility in Northern New Jersey, in close proximity to top pharmaceutical companies. In 2006, SGS expanded its US market presence by acquiring Northview Laboratories, which added an existing facility in the Chicago suburb of Northbrook, Illinois. From this current facility in Northbrook, SGS LSS will move to a new site in Lincolnshire, Illinois, doubling the facility size from 21,500 square feet to almost 40,000 square feet. As part of the move, SGS will increase its offerings in Stability Studies and Stability Program Management. Concurrently, SGS LSS plans to double the technical staffing by the end of the first quarter of 2010. Modifications to the building are currently in progress, with move-in targeted by the end of 2009.

“For SGS’s Life Science Services, the expansion at these two sites demonstrates our continued commitment to delivering excellent quality and service,” said Sohil Mana, Sr. Vice President and Regional Business Manager for North America.

“The move also involves the implementation of Lean Projects to increase efficiencies in our laboratories. These projects will strengthen our performance by developing innovative solutions to lead the industry in on-time delivery. Given that outsourcing is a continuing trend within the pharmaceutical market, these recent expansions will contribute to positioning SGS Life Science Services as the preferred partner for the pharmaceutical and biotechnology industries,” he added.

With 14 contract analytical laboratories, SGS can leverage its strong global network to deliver harmonized solutions to large pharmaceutical firms. In addition to testing services for the pharmaceutical market, SGS offers consultancy in regulatory affairs, inspection services and second- and third-party Good Manufacturing Practices (GMP) auditing services, impacting both regional and multinational companies sourcing raw materials globally.

For further information, please contact:

Ferdinand Dabu
Global Marketing Director
SGS Life Science Services

75 Passaic Avenue,
Fairfield, NJ 07004, USA
t: +1-973-276-8463

About SGS

SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 56,000 employees, SGS operates a network of over 1,000 offices and laboratories around the world.